

EDCTP Strategic action for overcoming drug resistance in malaria 2018	EDCTP Strategic action for the comparison, selection and development of malaria vaccine candidates 2018	EDCTP Vaccines for diarrhoeal diseases or lower respiratory tract infections 2018
The European & Developing Countries Clinical Trials Partnership (EDCTP) funds clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.		
APPLICATION DEADLINE	APPLICATION DEADLINE	APPLICATION DEADLINE
30 October 2018, 17:00	1 November 2018, 17:00	30 October 2018, 17:00
BACKGROUND	BACKGROUND	BACKGROUND
<p>There is a need to develop safe and effective drugs that can be used to progress the malaria elimination agenda, and with a particular emphasis on pregnant women, infants and children. Current treatment of malaria is highly dependent on artemisinin-based combination therapies (ACT), but emerging resistance has highlighted the need to develop a broader portfolio of antimalarial drugs, including new or repurposed non-ACT drugs for chemoprevention and treatment as well as long-acting products with transmission blocking potential. Clinical trials to support the product approval process for new drugs are often large in scale, complex and prohibitively expensive for a single funder. Coordination and collaboration between partners and funders is therefore essential to leverage sufficient expertise, resources and investments for accelerating the development of new or improved products and maximise the impact of research investments.</p>	<p>An effective and affordable malaria vaccine would present a major tool towards the eradication of malaria. The recently licensed malaria vaccine for human use (RTS,S) is an important step in this direction, but it is crucial to develop new and more effective second generation vaccines superior to RTS,S. A number of promising second generation vaccine candidates are currently under clinical or advanced preclinical development. Clinical trials to support the product approval process are often large in scale, complex and prohibitively expensive for a single funder. Coordination and collaboration between partners and funders is therefore essential to leverage sufficient expertise, resources and investments for accelerating the development of new or improved products and maximise the impact of research investments.</p>	<p>Vaccines have contributed enormously towards the elimination of diseases, including the control of infectious diseases in low resource settings. Development of vaccines against diarrhoeal diseases or lower respiratory tract infections is therefore one of the preferred strategies to reduce the high mortality and morbidity of these diseases. While investment in clinical development of vaccines for diarrhoeal diseases and lower respiratory tract infections has become more substantial, additional resources are needed to support clinical trials for these vaccine candidates in sub-Saharan Africa.</p>
ELIGIBILITY CRITERIA		
<ul style="list-style-type: none"> • Consortia comprising a minimum of three independent legal entities are eligible to apply. Two of the legal entities shall be established in two different Participating States (European Partner States)* and one of the legal entities must be established in a sub-Saharan African country**. • All three legal entities shall be independent of each other. • ‘Sole participants’ formed by several legal entities (e.g. European Research Infrastructure Consortia, European Groupings of Territorial Cooperation, central purchasing bodies) are eligible if the above-mentioned minimum conditions are satisfied by the legal entities forming together the sole participant. 		
A proposal/application will only be considered eligible if:		

- its content corresponds, wholly or in part, to the topic/contest description for which it is submitted
- it complies with the eligibility conditions set out in the table below, depending on the type of action

WHAT THE GRANT WILL COVER	WHAT THE GRANT WILL COVER	WHAT THE GRANT WILL COVER
<ul style="list-style-type: none"> • The call budget is EUR 22 million. • The requested EDCTP contribution per project should not exceed EUR 22 million. • The funding level is 100% of eligible costs. 	<ul style="list-style-type: none"> • The call budget is EUR 18 million. • The funding level is 100% of eligible costs. 	<ul style="list-style-type: none"> • The call budget is EUR 23 million. • EDCTP considers that proposals requesting a contribution from the EDCTP2 of between EUR 5 and 10 million would allow this specific challenge to be addressed appropriately. • The funding level is 100% of eligible costs.

HOW TO APPLY

The application must be submitted online via [EDCTPgrants](#)

- [Template of application form – Letter of Intent](#) (Word)
- Only registered users of EDCTPgrants system can apply for grants and therefore you are advised to register on the system as soon as possible.

Should you have any queries, kindly contact:

- For questions related to this call for proposals, please contact: Dr Michelle Helinski at helinski@edctp.org
- For questions and issues about EDCTPgrants and the online application submission please contact EDCTP via edctpgrants@edctp.org
- For guidance on online application procedure, please refer to the Guidance for applicants
- For more information about EDCTP2 procedures, please refer to the EDCTP2 Grants Manual and EDCTP2 FAQs.

APPLICATION DEADLINE	APPLICATION DEADLINE	
30 October 2018, 17:00	1st November 2018, 17:00	30 October 2018, 17:00